Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663369 | 0.82 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL9661871 | 0.81 | SMN1; SMN2 (0.43) | SLC6A2SLC6A4SLC6A3ALDH1A1KDM4E | |
| SCHEMBL24925875 | 0.80 | CYP1A2 (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL2763161 | 0.78 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3SLC10A1ALDH1A1 | |
| SCHEMBL5568080 | 0.77 | CYP1A2 (0.45) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL477369 | 0.76 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3SLC10A1ALDH1A1 | |
| SCHEMBL23610049 | 0.76 | CYP3A4 (0.48) | SLC6A2SLC6A4SLC6A3SLC10A1ALDH1A1 | |
| SCHEMBL20604265 | 0.76 | CYP3A4 (0.47) | SLC6A2SLC6A4SLC6A3SLC10A1ALDH1A1 | |
| SCHEMBL3103040 | 0.76 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL23610057 | 0.76 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3SLC10A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | ASTRAZENECA AB (SE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | ASTRAZENECA AB (SE) | 2012-11-01 | — | — | US | disclosed |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | BALESTRA MICHAEL (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2391606-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, HTR5A, TPH2 | SLC6A2 42/4885SLC6A4 29/4885SLC6A3 86/4885 |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, TPH1, TPH2 | SLC6A2 14/4885SLC6A4 15/4885SLC6A3 52/4885 |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | TPH1, TPH2, PNMT | SLC6A2 53/4885SLC6A4 36/4885SLC6A3 100/4885 |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | HTR5A, PNMT, GRIK5 | SLC6A2 83/4885SLC6A4 51/4885SLC6A3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.